Picture EBD Group Connector Personal Networking in Life Sciences 650x80
Document › Details

BioNTech AG. (2/22/17). "Press Release: BioNTech to Present at Cowen and Company’s 37th Annual Health Care Conference". Mainz.

Region Region Boston, MA
  Country United States (USA)
Organisations Organisation BioNTech AG
  Today BioNTech SE (Nasdaq: BNTX)
  Group BioNTech (Group)
  Organisation 2 Cowen & Company LLC
  Group Cowen (Group)
Products Product Cowen & Co. Annual Health Care Conference 2017 Boston
  Product 2 mRNA-based vaccine
Index terms Index term BioNTech–Cowen: investor conference, 201703 supply service BioNTech presents at Cowen & Co Annual Health Care Conference 2017
  Index term 2 BioNTech–ICR: public relations, 201712 service existent by ICR Healthcare in US
Persons Person Marett, Sean (BioNTech 202012 CBO + CCO 201506 COO before Evotec)
  Person 2 Jehle, Regina (Abivax 201912– Director of Communications before BioNTech 2014– 2019)

BioNTech AG, a fully integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that Sean Marett, COO of BioNTech, will be presenting at Cowen and Company’s 37th Annual Health Care Conference that is being held in Boston, MA from March 6 - 8, 2017. The presentation is scheduled for Tuesday, March 7 at 10:00AM Eastern Standard Time.

Mr. Marett will provide an overview of the Company´s strategy and its most recent substantial progress, including an update of its clinical pipeline, an overview of its strategic collaborations, a summary of its two most recent Nature publications related to its individualized mRNA cancer immunotherapeutics and the establishment of a GMP conform mRNA production facility at the Company´s headquarters in Germany.

About BioNTech AG

BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks for individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech´s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly & Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder. More information about BioNTech is available at

For meeting requests or further information, please contact:

BioNTech AG
Regina Jehle
Tel: +49 6131 9084 1273

U.S. Media and Investor Inquiries:

ICR, Inc.
James Heins/Stephanie Carrington
Tel: +1 203 682 8251
Tel: +1 646 277 1282

International Media & Investor Inquiries:

Dr. Ludger Wess / Ines-Regina Buth
Tel: +49 40 8816 5964
Tel: +49 30 2363 2768

Record changed: 2021-04-27


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

More documents for BioNTech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

» top